Short Reads

Premium

Novartis is breaking up the Genome & Proteome Sciences program within the Cambridge, Mass.-based Novartis Institutes for Biomedical Research in order to restructure and refocus its programs and resources. The company will continue ongoing projects, but most of the staff and programs will be absorbed by other units within the pharma.

Agilent Technologies plans to acquire Stratagene for about $246 million in cash, representing a 28 percent premium above Stratagene’s stock price the day before the acquisition was announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.